Send to printer »

GEN News Highlights : Feb 8, 2007

Crucell and DSM Add Protein Production to PER.C6

Deal will include new classes of proteins, including biosimilar protein products.

DSM Biologics and Crucell are expanding their existing PER.C6® commercial relationship to include new classes of proteins, including biosimilar protein products. The goal is to provide a solution for the production of pharmaceutical proteins to licensees utilizing PER.C6 in the biotech industry.

As part of the agreement, DSM paid Crucell an undisclosed amount in exchange for additional license rights and a higher share of future licensing income.

Since December 2002, DSM Biologics and Crucell have jointly outlicensed PER.C6 human cell line to companies as a production platform for Mabs and recombinant proteins. The parties recently established the PERCIVIA PER.C6® Development Center in Cambridge, MA, as a joint venture.